Handelsavisen
prelaunch
Companies ›Healthcare ›TRI.AX
TR
TRI.AX — ASX Pharmaceuticals

Tri.Ax

A$0,02
Open in Charts → Attach watcher ⌖
— —
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-80,6 %
ROE
-7,4 %
Net margin
-83,5 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

TRI.AX operates in the pharmaceuticals industry, focusing on the development and commercialization of medical research and pharmaceutical products.

Business. TRI.AX operates in the pharmaceuticals industry, focusing on the development and commercialization of medical research and pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-7,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TRI.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TRI.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TRI.AX operates in the pharmaceuticals industry, focusing on the development and commercialization of medical research and pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    TRI.AX has a liquidity position that is characterized by a current ratio of 1.86, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's operating cash flow is negative at -161,650 AUD, and its free cash flow is significantly negative at -2,982,090 AUD, which suggests that the company is not generating enough cash from operations to fund its activities or to service its debt.

    In terms of profitability, TRI.AX is currently unprofitable, with an operating income of -909,600 AUD and a net income of -943,230 AUD. The company's return on equity is -7.45%, and its return on assets is -7%, both of which are below the industry norms for a profitable pharmaceutical company. These metrics indicate that the company is not effectively utilizing its equity and assets to generate returns.

    TRI.AX's revenue is concentrated in a single segment, as the financial data does not provide a breakdown of revenue by geographic regions or business segments. The company's total revenue for the period is 1,128,980 AUD, and there is no indication of significant diversification in its revenue streams.

    The growth trajectory of TRI.AX is currently negative, as the company is experiencing a decline in profitability and is not generating positive cash flows. The company's capital expenditure for the period is -2,091,330 AUD, which indicates that the company is not investing in new projects or expanding its operations. The outlook for the company's revenue and profitability is uncertain, and there is no indication of a turnaround in the near future.

    The risk assessment for TRI.AX indicates a medium level of liquidity risk, with a key flag noting that the company's net cash is negative after subtracting total debt. The dilution risk is assessed as low, and there are no significant dilution sources identified in the financial data. The company's debt to equity ratio is 0.01, which is relatively low, but the negative cash flows and unprofitability pose a risk to the company's financial stability.

    There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial performance and position are primarily based on the latest available financial data, and there is no indication of any major events that have occurred recently.

    Key takeaways
    • TRI.AX is currently unprofitable with a negative operating and net income.
    • The company's liquidity position is medium, with a current ratio of 1.86 but negative operating and free cash flows.
    • TRI.AX's return on equity and return on assets are both negative, indicating poor utilization of equity and assets.
    • The company's capital expenditure is negative, suggesting no investment in new projects or expansion.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,02
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    A$12.7M
    Net cashⓘ
    -A$169.0k
    Current ratioⓘ
    1.9
    Debt / equityⓘ
    0.0
    ROAⓘ
    -7.0%
    ROEⓘ
    -7.4%
    Cash conversionⓘ
    17.0%
    CapEx / revenueⓘ
    -1.9%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-80,6 %Bottom quartile
    Net Margin-83,5 %Bottom quartile
    ROE-7,4 %Bottom quartile
    Capex / Rev-185,2 %Bottom quartile
    D/E0,01Above median
    Cash Conv0,17Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TRI.AX Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    13.9Mshares short-4.9% vs prior
    7.3days to cover
    85.5%short of daily vol
    23.3Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TRI.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage